ProFibrix and CSL Behring Enter Into Fibrinogen and Thrombin Supply AgreementBy Profibrix B.v., PRNE
Wednesday, June 16, 2010
LEIDEN, The Netherlands and SEATTLE, June 17, 2010 - ProFibrix B.V., a leader in the development of innovative
products for hemostasis and regenerative medicine, today announced that it
has entered into an agreement with CSL Behring for the clinical and
commercial supply of plasma-based fibrinogen and thrombin, for the
manufacturing of Fibrocaps(TM). CSL Behring is a leader in the plasma protein
therapeutics industry and a subsidiary of CSL Limited (ASX: CSL), a global
biopharmaceutical company headquartered in Melbourne, Australia.
Jaap Koopman, CEO of ProFibrix said: "We are extremely pleased
with the supply agreement with CSL Behring. CSL Behring is one of the
acknowledged global leaders in the plasma protein therapeutic industry.
Importantly, the agreement will enable us to use CSL Behring's fibrinogen and
thrombin, approved in markets around the world, as active components in our
lead product Fibrocaps. This will offer us a tremendous advantage with
regulatory authorities when seeking approval for Fibrocaps."
Fibrocaps is based on a mixture of two essential blood
clotting proteins, fibrinogen and thrombin, and is a unique dry powder
topical tissue sealant in development to stop bleeding after or during
surgery. Fibrocaps is clearly differentiated from existing liquid tissue
sealants and hemostats: it is ready for immediate use, is stable at room
temperature, and has shown to be safe and efficacious in the first Phase II
study conducted in EU. ProFibrix is starting a global Phase II study in the
summer of 2010.
ProFibrix (www.ProFibrix.com) was founded in 2004 and
is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle,
WA, USA. The company leverages its expertise in fibrinogen technology to
develop and market innovative products for the hemostasis and regenerative
medicine markets. Human fibrinogen plays a pivotal role in blood clotting and
tissue healing. ProFibrix is led by a team with extensive commercial,
clinical and scientific experience in the hemostasis field.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry.
Committed to saving lives and improving the quality of life for people with
rare and serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide. CSL Behring therapies are
indicated for the treatment of coagulation disorders including hemophilia and
von Willebrand disease, primary immune deficiencies, inherited respiratory
disease and hereditary angioedema. The company's products are also used in
cardiac surgery, organ transplantation, burn treatment and to prevent
hemolytic diseases in newborns. CSL Behring operates one of the world's
largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary
of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in
Melbourne, Australia. For more information, visit www.cslbehring.com.
ProFibrix B.V., Jaap Koopman, Ph.D., CEO, Tel: +31(0)6-21628475, E-mail: j.koopman at profibrix.com; ProFibrix Inc., Jan Ohrstrom, MD, COO, Tel: +1-2069105404, E-mail: j.ohrstrom at profibrix.com
Tags: June 17, Leiden, Netherlands, ProFibrix B.V., The Netherlands And Seattle, United States of America